Nevirapine Moringside Healthcare

Nevirapine, the active ingredient in Nevirapine Moringside Healthcare, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of HIV‑1 infection, typically as part of combination antiretroviral therapy in adults and adolescents.

GNH USA supplies Nevirapine Moringside Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Nevirapine is a non‑nucleoside reverse transcriptase inhibitor used in antiretroviral therapy for HIV‑1 infection.

- Initial HIV‑1 infection: reduces viral load when combined with other antiretroviral agents. - Treatment‑experienced HIV‑1 infection: provides an additional mechanism of action in salvage regimens. - HIV‑1 infection in pregnant women (category B): used under medical supervision as part of combination therapy.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal discomfort. - Headache: transient mild headaches. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools, usually self‑limiting. - Elevated liver enzymes: mild hepatic enzyme changes.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatotoxicity: significant liver injury, potentially leading to jaundice. - Severe hypersensitivity: systemic allergic response with fever and malaise. - Neutropenia: marked reduction in white blood cells. - Anaphylaxis: rare life‑threatening allergic reaction. - Autoimmune hepatitis: immune‑mediated liver inflammation.

Nevirapine requires careful monitoring and patient education to minimize risks.

- Liver monitoring: assess hepatic function before initiation and regularly during therapy. - Rash assessment: examine any skin changes promptly; discontinue if severe. - Pregnancy counseling: use only when benefits outweigh risks; monitor fetal development. - Hepatic impairment: adjust therapy and monitor closely in patients with existing liver disease. - Drug hypersensitivity: avoid in individuals with known hypersensitivity to nevirapine or other NNRTIs. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nevirapine interacts with several medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Rifampicin: strong enzyme inducer that markedly reduces nevirapine plasma levels. - St. John’s wort: herbal inducer leading to subtherapeutic concentrations. - Concurrent NNRTIs: additive toxicity and overlapping mechanisms.

Moderate Interactions (Monitor Closely): - Azidothymidine (AZT): may increase risk of hepatotoxicity. - Hormonal contraceptives: reduced efficacy, consider alternative contraception. - Warfarin: potential alteration of INR, monitor coagulation parameters. - Protease inhibitors (e.g., ritonavir): may increase nevirapine levels, adjust dose if needed.